Create a free research account to view current pricing and place an order.
Mechanism of action
PT-141/bremelanotide is a melanocortin receptor agonist, primarily acting through MC3R/MC4R pathways associated with sexual arousal signaling and central nervous system melanocortin activity.
Half-life & pharmacokinetics
Half-life: Approx. 2.7 hours for approved bremelanotide formulation.
FDA labeling for bremelanotide describes a terminal half-life of about 2.7 hours, with peak concentration around 1 hour in clinical autoinjector formulations.
Research dosing reference
1.25-1.75 mg PRN research reference; avoid frequent repeated exposure.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 1.25 mg | 25 units |
| 1.75 mg | 35 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Typically timed several hours before intended effect window; avoid first exposure in high-stakes situations.
Beginner escalation
Start conservatively due to nausea, flushing, blood pressure, and CNS-response variability.
Side-effect mitigation
Monitor nausea, flushing, headache, blood pressure changes, hyperpigmentation risk, and prolonged arousal response.
Stack compatibility
Avoid stacking with other melanocortin agents or BP-active compounds without review.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Use as intermittent/situational exposure, not continuous daily cycling. Reassess frequency, blood pressure response, nausea, and melanocortin-related effects before repeat use.
Frequently asked questions
What is PT-141 and how does it work?
PT-141/bremelanotide is a melanocortin receptor agonist, primarily acting through MC3R/MC4R pathways associated with sexual arousal signaling and central nervous system melanocortin activity.
What is the half-life of PT-141?
PT-141: Approx. 2.7 hours for approved bremelanotide formulation. FDA labeling for bremelanotide describes a terminal half-life of about 2.7 hours, with peak concentration around 1 hour in clinical autoinjector formulations.
How is PT-141 reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is PT-141 FDA approved?
No. PT-141 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
PT-141 product overview · PT-141 cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration